Fig. 3From: Effectiveness of rituximab in neuromyelitis optica: a meta-analysisForest Plot Showing the EDSS score of Patients with NMO after Rituximab Therapy. The estimated pooled weighted mean difference was − 1.16 was highly significant (p < 0.0001), there was a moderate heterogeneity of study results (I2 = 15.5%)Back to article page